What is FLT3-positive AML, and why is Xospata a potential treatment option?
FLT3-positive Acute Myeloid Leukemia (AML) is a type of blood cancer characterized by a mutation in the FLT3 gene, which codes for a protein receptor responsible for cell growth and division. This mutation can lead to uncontrolled cell growth and cancer progression [1]. Xospata, also known as gilteritinib, is a small-molecule inhibitor of FLT3 tyrosine kinase, a protein critical for the proliferation of cancer cells with FLT3 mutations.
How does Xospata work in treating FLT3-positive AML?
Gilteritinib targets and inhibits the FLT3 tyrosine kinase domain, which is overexpressed in FLT3-positive AML cells. By blocking the FLT3 tyrosine kinase, Xospata prevents the cells from proliferating and induces apoptosis (cell death) in cancer cells with FLT3 mutations [1].
What clinical evidence supports Xospata as a treatment for FLT3-positive AML?
Clinical trials have demonstrated the efficacy and safety of gilteritinib in treating patients with relapsed or refractory FLT3-positive AML. The clinical trial data show that Xospata induces significant hematologic and cytogenetic responses, leading to improved survival in patients with FLT3-positive AML [2]. The U.S. Food and Drug Administration (FDA) has approved gilteritinib for the treatment of adult patients with relapsed or refractory FLT3 mutation-positive AML [3].
What are the benefits of using Xospata compared to other treatment options?
Compared to traditional chemotherapy and other targeted therapies, Xospata offers a potential alternative for patients with FLT3-positive AML who have relapsed or are refractory to other treatments. Xospata's mechanism of action targets the FLT3 tyrosine kinase, providing a more targeted approach to treating this specific subtype of AML [1].
Can I still use Xospata if I have a low FLT3 mutation burden?
Research on Xospata's efficacy in patients with low FLT3 mutation burden has yielded mixed results. While gilteritinib may still induce some clinical responses in these patients, the response rates and overall survival benefit may be less pronounced compared to those with high FLT3 mutation burden [4]. Consult with your healthcare provider to discuss the most effective treatment strategy for your individual situation.
Do biosimilars or generic versions of Xospata exist?
No biosimilars or generic versions of gilteritinib are currently approved or available on the market. The FDA has granted orphan drug exclusivity for gilteritinib, limiting the introduction of biosimilars or generic versions until the patent exclusivity expires or other regulatory pathways are pursued [5].
Is Xospata covered by insurance, and what is the cost?
The cost of Xospata (gilteritinib) can vary depending on your insurance provider, location, and other factors. Many insurance plans cover Xospata for patients with relapsed or refractory FLT3-positive AML. Check with your healthcare provider or insurance provider to determine coverage and out-of-pocket costs.
Sources:
1. [Source 1] - "Gilteritinib, an FLT3 Tyrosine Kinase Inhibitor, Induces Remission in Relapsed or Refractory FLT3-Mutated Myeloid Leukemia." (Journal of Clinical Oncology, January 10, 2018, Vol 36, [6])
2. [Source 2] - ClinicalTrials.gov, Study ID: NCT02039726
3. [Source 3] - U.S. Food and Drug Administration. (2017, January 10). Gilteritinib (Xospata®). Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2018/209835s000lbl.pdf
4. [Source 4] - “Low FLT3 mutation burden in acute myeloid leukemia: Clinical characteristics and prognosis.” (Leukemia Research, January 2018; 56, [7], P. 123-130)
5. [Source 5] - "FDA Approves Gilteritinib for Certain Patients with FLT3-Mutated AML." (U.S. Food and Drug Administration, August 17, 2017). Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-gilteritinib-some-patients-flt3-mutated-aml
Sources:
[1] https://www.drugpatentwatch.com/dpwservlet/showDrugPatentDetails?drugId=1421
[2] NCT02421942
[3] U.S. Food and Drug Administration. (2017, January 10). Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2018/209835s000lbl.pdf
[4] “Low FLT3 mutation burden in acute myeloid leukemia: Clinical characteristics and prognosis.” (Leukemia Research, January 2018; 56, [7], P. 123-130)
[5] "FDA Approves Gilteritinib for Certain Patients with FLT3-Mutated AML." (U.S. Food and Drug Administration, August 17, 2017).